Durable Maintenance of EASI-90 With Amlitelimab in Adults With Moderate-to-Severe Atopic Dermatitis: 52-Week Results from the STREAM-AD Phase 2b Trial. J of Skin 2025, 9 (6), s606. https://doi.org/10.25251/yhn4cs07.